platoseedplatoseed
We teach your immune system to attack and cure cancer
Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise. Modulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue. Modulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.
Modulari-T is a bioscience company that positions itself as delivering next-generation immune receptors and delivery vectors for cell and gene therapies, aiming to overcome limitations of first-gen CAR-T and related treatments. Their two technologies, MARC and MoVe, are presented as components of a unified system intended to enable targeted, controlled, and potentially broader immune-based therapies. The messaging emphasizes in vivo delivery, reduced toxicity, and applicability across multiple cell types.
They offer two technologies within a single system: MARC (Modular Actuation Receptor Complex), a next-generation immune receptor with separate targeting and signaling, featuring on/off control, reduced exhaustion, and validation across five cell types; and MoVe (Modular Vector), a delivery vehicle designed for in vivo cell and gene therapy with no liver toxicity and the ability to precisely target immune or non-immune cells.
Who it’s for: Biotech/pharma researchers and developers focused on cell therapy, gene therapy, and immuno-oncology; translational researchers and biotech companies seeking next-generation receptor and delivery platform capabilities.
branding and pipeline emphasis; mentions of a 2026 date and a dedicated pricing page, but no explicit funding, hiring, or traction details provided
David is the CEO and cofounder of Modulari-T. His expertise spans multiple areas and he is driven by a passion for pushing the boundaries of technology. During his PhD he discovered how protein receptors form complex structures that allow them to alter cells’ behavior. He then took this knowledge and the novel technology that was developed to build Modulari-T. When he’s not thinking up a new way to engineer cells he can be spotted biking or running up a mountain.
Co-founder and COO at Modulari-T. PhD in chemical engineering. Technical background in synthetic biology, advanced 3D cell culture systems, and biomaterials in the context of the cellular cancer microenvironment. Fascinated by the innovations cell-based therapies, food products, and the scale up of their manufacturing. Gave the unconference talk "Lessons learned and mistakes made growing the world's hottest peppers".
We teach your immune system to attack and cure cancer.
Modulari-T is a cell therapy company that uses the Modular Actuation Receptor Complex (MARC) platform to reprogram immune cells to recognize cancer antigens, aiming for higher tumor clearance with fewer side effects. They announce MARC enables cancer treatment and broader applications beyond oncology, and invite partnerships and hires.
From the original launch (Jan 2023) — may be outdated.
Reprogramming Immunity for Target-Specific Medicines
Kernal is creating mRNA 2.0 therapies that work in specific cells
